rs63750749
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000249.4(MLH1):c.1190delT(p.Leu397ArgfsTer4) variant causes a frameshift change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,890 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000249.4 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461890Hom.: 0 Cov.: 34 AF XY: 0.00 AC XY: 0AN XY: 727248
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Colorectal cancer, hereditary nonpolyposis, type 2 Pathogenic:1
This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. -
Lynch syndrome Pathogenic:1
Coding sequence variation resulting in a stop codon -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change creates a premature translational stop signal (p.Leu397Argfs*4) in the MLH1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MLH1 are known to be pathogenic (PMID: 15713769, 24362816). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with colorectal cancer (PMID: 10196371, 25559809). ClinVar contains an entry for this variant (Variation ID: 89673). For these reasons, this variant has been classified as Pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.1190delT pathogenic mutation, located in coding exon 12 of the MLH1 gene, results from a deletion of one nucleotide at position 1190, causing a translational frameshift with a predicted alternate stop codon (p.L397Rfs*4). This alteration was first reported in the literature in a female diagnosed with endometrial cancer at age 52 and colon cancer at age 55 (Millar AL et al. Hum Mol Genet.1999 May;8(5):823-9). Subsequently, this alteration was identified in a male diagnosed with gastric cancer at age 35 that was MSI-High and IHC staining showed loss of MLH1; however, the patient did not have a family history of cancer (Bacani J et al. J Mol Diagn. 2005 Oct;7:465-77). This mutation was also identified in a female diagnosed with colon cancer at age 48 who met Bethesda criteria; however, her colon tumor was MSI-Low and IHC staining showed loss of MLH1, MSH2, and MSH6 (Barnetson RA et al. N. Engl. J. Med. 2006 Jun;354:2751-63). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
not provided Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at